Phosphorylation and hydroxylation are post translational modifications (PTMs) rarely observed or reported in biopharmaceuticals. While developing a stable CHO cell line and a fed-batch process to produce a biosimilar dulaglutide, a GLP1-Fc fusion protein, the authors identified both serine phosphorylation and lysine hydroxylation. While the innovator dulaglutide contains less than 2% phosphorylated and only ≈6.5% hydroxylated GLP1-Fc molecules, the clones that the authors obtained in the platform fed-batch process have ≈20% phosphorylated and 25% hydroxylated GLP1-Fc molecules. An optimization of the nutrient feed is carried out, which successfully reduces the phosphorylation level to ≈3% and the hydroxylation level to 9.4% using the lead clone. Four components, cysteine, vitamin C, ferric citrate, and niacinamide, are found to be important in reducing the phosphorylation level. An increase in vitamin C, ferric citrate, and niacinamide feeding rates and a decrease in the cysteine feeding rate helps to reduce the phosphorylation level. Niacinamide and cysteine are also found to be critical for hydroxylation. An increase in the niacinamide and cysteine feeding rate is beneficial in reducing the hydroxylation level. This study is the first to report the impact of nutrient components on serine phosphorylation and lysine hydroxylation in biopharmaceuticals.
Keywords: GLP1 analog; flexible linker; fusion protein; glycine-serine linker; hydroxylation; phosphorylation.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.